This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Alliance Pharma Future Growth

Future criteria checks 4/6

Alliance Pharma is forecast to grow earnings and revenue by 69.8% and 7.1% per annum respectively. EPS is expected to grow by 100.1% per annum. Return on equity is forecast to be 12% in 3 years.

Key information

69.8%

Earnings growth rate

100.09%

EPS growth rate

Pharmaceuticals earnings growth	10.1%
Revenue growth rate	7.1%
Future return on equity	12.00%
Analyst coverage	Good
Last updated	28 Apr 2025

Recent future growth updates

Recent updates

Analysis Article • Sep 10

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

It's shaping up to be a tough period for Alliance Pharma plc ( LON:APH ), which a week ago released some disappointing...

Analysis Article • Sep 30

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analysis Article • May 28

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Today we will run through one way of estimating the intrinsic value of Alliance Pharma plc ( LON:APH ) by taking the...

Analysis Article • Mar 30

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Analysis Article • Dec 24

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...

Analysis Article • Nov 19

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Alliance Pharma's (LON:APH) stock up by 2.2% over the past three months. As most would know, long-term fundamentals...

Earnings and Revenue Growth Forecasts

AIM:APH - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	214	26	N/A	N/A	1
12/31/2026	211	25	34	43	6
12/31/2025	201	21	31	41	6
12/31/2024	179	-11	41	39	N/A
9/30/2024	181	-22	35	34	N/A
6/30/2024	183	-34	29	30	N/A
3/31/2024	182	-33	30	31	N/A
12/31/2023	181	-33	31	31	N/A
9/30/2023	175	-31	30	30	N/A
6/30/2023	170	-29	29	29	N/A
3/31/2023	169	-25	25	25	N/A
12/31/2022	167	-21	20	21	N/A
9/30/2022	165	-5	26	27	N/A
6/30/2022	163	12	32	34	N/A
3/31/2022	163	10	33	36	N/A
12/31/2021	163	7	34	39	N/A
9/30/2021	155	13	34	39	N/A
6/30/2021	147	18	34	39	N/A
3/31/2021	138	13	36	40	N/A
12/31/2020	130	8	38	42	N/A
9/30/2020	131	10	33	37	N/A
6/30/2020	131	11	29	32	N/A
3/31/2020	133	18	30	34	N/A
12/31/2019	136	25	32	36	N/A
9/30/2019	133	23	28	32	N/A
6/30/2019	130	21	24	27	N/A
3/31/2019	124	20	21	25	N/A
12/31/2018	118	18	19	22	N/A
9/30/2018	112	21	N/A	24	N/A
6/30/2018	107	24	N/A	26	N/A
3/31/2018	104	27	N/A	27	N/A
12/31/2017	102	29	N/A	27	N/A
9/30/2017	101	25	N/A	27	N/A
6/30/2017	100	22	N/A	26	N/A
3/31/2017	99	20	N/A	22	N/A
12/31/2016	97	18	N/A	17	N/A
9/30/2016	85	18	N/A	13	N/A
6/30/2016	72	18	N/A	9	N/A
3/31/2016	60	15	N/A	9	N/A
12/31/2015	48	13	N/A	8	N/A
9/30/2015	47	11	N/A	9	N/A
6/30/2015	45	8	N/A	9	N/A
3/31/2015	44	8	N/A	10	N/A
12/31/2014	44	8	N/A	11	N/A
9/30/2014	44	8	N/A	11	N/A
6/30/2014	44	9	N/A	10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: APH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: APH is expected to become profitable in the next 3 years.

Revenue vs Market: APH's revenue (7.1% per year) is forecast to grow faster than the UK market (3.9% per year).

High Growth Revenue: APH's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: APH's Return on Equity is forecast to be low in 3 years time (12%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 08:49
End of Day Share Price	2025/05/13 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alliance Pharma plc is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Samuel England	Berenberg
Julie Simmonds	Canaccord Genuity
Mark Brewer	Cavendish

This company listing is no longer active

Alliance Pharma Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023

Price target decreased by 7.9% to UK£0.75

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 11%

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insider recently sold UK£200k worth of stock

New major risk - Share price stability

First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023)

Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Alliance Pharma plc Announces Jeyan Heper to Leave the Business as Chief Operating Officer, Effective 31 August 2024

Is Alliance Pharma (LON:APH) A Risky Investment?

Alliance Pharma plc, Annual General Meeting, Jul 29, 2024

New minor risk - Financial position

Full year 2023 earnings: EPS misses analyst expectations

Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023

Alliance Pharma plc to Report Fiscal Year 2023 Results on Jun 19, 2024

New minor risk - Share price stability

Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies

Alliance Pharma plc Announces CEO Changes

Alliance Pharma plc to Report Fiscal Year 2023 Results on Apr 09, 2024

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Alliance Pharma plc Announces Board Changes

Price target decreased by 7.9% to UK£0.75

High number of new directors

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Alliance Pharma plc Announces Appointment of Non-Executive Directors

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc to Report First Half, 2023 Results on Sep 26, 2023

Upcoming dividend of UK£0.012 per share at 3.1% yield

Consensus EPS estimates fall by 13%

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 11%

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased by 9.1% to UK£0.92

Alliance Pharma plc Appoints Martin Sutherland as Non-Executive Director

Price target decreased to UK£0.97

Alliance Pharma plc to Report Fiscal Year 2022 Final Results on Mar 21, 2023

Alliance Pharma plc Announces Executive Changes

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 17%

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of UK£0.011 per share

Insufficient new directors

Price target increased to UK£1.25

Price target increased to UK£1.20

First half 2021 earnings released: EPS UK£0.015 (vs UK£0.003 loss in 1H 2020)

Upcoming dividend of UK£0.011 per share

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Independent Non-Executive Director has left the company

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Full year 2020 earnings released: EPS UK£0.015 (vs UK£0.048 in FY 2019)

Price target lowered to UK£1.11

Price target raised to UK£1.00

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

New 90-day high: UK£0.79

New 90-day high: UK£0.77